Compared with no study treatment ( n = @ ) , rifaximin ( n = @ ) use was associated with a significant difference between study arms in the change from baseline to week @ for CD@ ( + ) T-cell activation ( median change , @ % with rifaximin vs +@ % with no treatment ; P = @ ) .